Invitrogen Corporation Launches New Microarray System to Simplify Immunogenetic Testing

CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the commercial availability of a state-of-the-art, automated, research-use microarray system designed to simplify immunogenetic testing, including human leukocyte antigen (HLA) research. The new Prodigy™ system is an advanced DNA and protein analysis tool that simplifies and accelerates histocompatibility research, vaccine and drug development, and disease association studies.